Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.

p53 mutations have been reported in cell lines derived from relapsed neuroblastoma tumors. We hypothesize that functional inactivation of p53 by mutation or other mechanisms is common in relapsed neuroblastoma and can contribute to chemoresistance. Our aim was to determine the frequency of p53 mutations, p14(ARF) methylation, or deletion and MDM2 amplification in 23 neuroblastoma cell lines (6 derived at diagnosis and 17 derived at relapse). One cell line was p53 mutant (BE2c) and two cell lines were deleted for p14(ARF) (LAN-6 and SHEP). Two cell lines were methylated for p14(ARF) (GIMEN and PER-108), one of which had low levels of p14(ARF) mRNA expression which increased following demethylation with 5-aza-2/deoxycytidine treatment (GIMEN), and four cell lines were confirmed to be MDM2-amplified. All these cell lines were derived from neuroblastomas at relapse. Inactivation of the p53 pathway was observed in 9 out of 17 neuroblastoma cell lines (53%) established at relapse and in none of the cell lines established from pretreatment tumors. If these data are confirmed in neuroblastoma tumors, this suggests that p53-independent therapy and reactivation of inactive p53 approaches would be useful in the management of relapsed neuroblastoma.

[1]  A. Pession,et al.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Gerald,et al.  Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. , 2004, Journal of the National Cancer Institute.

[3]  R. Gilbertson,et al.  The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. , 2004, Brain research. Molecular brain research.

[4]  D. Ellison,et al.  Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. , 2003, Carcinogenesis.

[5]  H. Hemmi,et al.  A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW. , 2003, The Tohoku journal of experimental medicine.

[6]  T. Taki,et al.  Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. , 2003, International journal of oncology.

[7]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[8]  M. Alonso,et al.  Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p. , 2003, European journal of cancer.

[9]  G. Johnson,et al.  Cdk5 phosphorylates p53 and regulates its activity , 2002, Journal of neurochemistry.

[10]  M. Valentine,et al.  Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN , 2002, Oncogene.

[11]  B. Corfe,et al.  Damage‐induced Bax N‐terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate , 2001, The EMBO journal.

[12]  W. London,et al.  p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  F. Wright,et al.  Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas–Implications for tumor biology and potential clinical utility , 2001, Oncogene.

[14]  C J Gomer,et al.  Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. , 2001, Cancer research.

[15]  J. Lunec,et al.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. , 2001, The American journal of pathology.

[16]  D. Woods,et al.  Regulation of p53 function. , 2001, Experimental cell research.

[17]  H. Moritake,et al.  Analysis of PTEN/MMAC1 alteration in neuroblastoma. , 2001, Cancer genetics and cytogenetics.

[18]  P. McKenzie,et al.  Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  G. Yang,et al.  Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[21]  Peter A. Jones,et al.  The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53 , 1998, Molecular and Cellular Biology.

[22]  D. Neal,et al.  Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. , 1998, British Journal of Cancer.

[23]  B. Stewart,et al.  The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. , 1997, European journal of cancer.

[24]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[25]  P. Houghton,et al.  Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[27]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Kastan,et al.  The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. , 1996, The American journal of pathology.

[29]  S. Cohn,et al.  Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[30]  S. Tavtigian,et al.  Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.

[31]  M. Schwab,et al.  Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. , 1995, Oncogene.

[32]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[33]  U. Kees,et al.  Three neuroblastoma cell lines established from consecutive samples of one patient which show distinct morphologic features, MYCN amplification, and surface marker expression. , 1992, Cancer genetics and cytogenetics.

[34]  S. Cohn,et al.  Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. , 1991, Cancer research.

[35]  H. Hameister,et al.  Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS , 1991, Human Genetics.

[36]  Joseph A. DiGiuseppe,et al.  Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. , 1990, Oncogene.

[37]  J. Wasson,et al.  Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. , 1987, Cancer research.

[38]  E. Frenkel,et al.  Characterization of human neuroblastoma cell lines established before and after therapy. , 1986, Journal of the National Cancer Institute.

[39]  J. Cowell,et al.  Chromosome analysis of human neuroblastoma cell line TR14 showing double minutes and an aberration involving chromosome 1. , 1983, Cancer genetics and cytogenetics.

[40]  F. Gilbert,et al.  Clonal evolution in a human neuroblastoma. , 1983, Journal of the National Cancer Institute.

[41]  L S Freedman,et al.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. , 1978, Cancer research.

[42]  G. S. Sekhon,et al.  Chromosomal aberrations in human neuroblastomas , 1977, Cancer.

[43]  W. W. Nichols,et al.  Definition of a continuous human cell line derived from neuroblastoma. , 1970, Cancer research.

[44]  A. Vicha,et al.  Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. , 2005, Neoplasma.

[45]  J. Lunec,et al.  Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. , 2001, Cancer research.

[46]  J. Maris,et al.  Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. , 2001, Cancer research.

[47]  A. Stavrovskaya.  Cellular mechanisms of multidrug resistance of tumor cells. , 2000, Biochemistry. Biokhimiia.

[48]  J. Houghton,et al.  Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. , 1998, Oncology research.

[49]  A. Davidoff,et al.  Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. , 1992, Oncogene.

[50]  G. Tonini,et al.  A New Human Highly Tumorigenic Neuroblastoma Cell Line with Undetectable Expression of N-myc , 1990, Pediatric Research.

[51]  M. Tomayko,et al.  Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. , 1988, Progress in clinical and biological research.